Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer  Anne Perdrix, Mathilde Saint-Ghislain, Marie Degremont, Marion David, Zena Khaznadar, Agnès Loeb, Marianne Leheurteur, Frédéric Di Fiore, Florian Clatot  Reproductive BioMedicine Online  Volume 35, Issue 4, Pages 468-474 (October 2017) DOI: 10.1016/j.rbmo.2017.06.005 Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Evolution of anti-Müllerian hormone (AMH) concentrations from the time of diagnosis to 1, 3 and 5 years after diagnosis. Each coloured line represents a patient. The median AMH decreases drastically 1 year after diagnosis (n = 49, P < 0.0001, comparing pre-diagnosis and 1-year post-diagnosis concentrations) and increases slightly 3 years after (n = 32, P = 0.007, comparing 1-year and 3-years post-diagnosis concentrations), but it does not recover to pretreatment concentrations. No further improvement is observed 2 years later (n = 9, P = 1, comparing 3-year and 5-years post-diagnosis concentrations). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Reproductive BioMedicine Online 2017 35, 468-474DOI: (10.1016/j.rbmo.2017.06.005) Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 Evolution of median anti-Müllerian hormone (AMH) concentrations from the pretreatment to 1, 3 and 5 years after the diagnosis, compared with the theoretical physiological AMH decrease. The solid line represents the AMH decrease observed in this study population, women <35 years treated for a breast cancer at 1, 3 and 5 years after the diagnosis. The dashed line represents the theoretical AMH decrease that would have been expected in this population without treatment. This decrease was calculated from the median AMH concentration observed in the population before the diagnosis, and assuming the physiological rate of decline of 5.6% per year (Bentzen et al., 2013). The AMH concentrations of the patients were reported using the median value. The 95% confidence intervals were calculated based on a bootstrap method using 10,000 permutations and were performed by the R free software. (*) indicates a significant difference (P < 0.0001) between the AMH measurements in patients, represented with the full line, and the expected AMH values according to the theoretical physiological AMH decrease, represented with the dashed line. Reproductive BioMedicine Online 2017 35, 468-474DOI: (10.1016/j.rbmo.2017.06.005) Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions